Medsol AI

MedSol AI Solutions is a pioneering South African healthtech company at the forefront of AI-driven healthcare innovation. Founded in 2020 by Dr. Kathryn Malherbe, a diagnostic radiographer with nearly two decades of clinical experience, the company develops cutting-edge deep machine learning and artificial intelligence solutions for early disease detection. With a mission to democratize access to quality diagnostics across Africa and beyond, MedSol AI is transforming how healthcare providers screen, diagnose, and treat patients in underserved communities where access to specialist care is limited.

The company’s flagship product, Breast AI, is an AI-enabled point-of-care ultrasound (POCUS) system that delivers real-time breast cancer risk assessment with over 90% diagnostic accuracy. Trained on more than 40,000 histologically confirmed cases, Breast AI integrates with wireless Clarius handheld ultrasound probes and operates via Android devices, enabling nurses and general practitioners in rural clinics to perform differential diagnoses on-site. This innovation has dramatically reduced patient referral times from six months to just one week, facilitating faster access to life-saving treatment. The solution is also 65% more affordable than competing technologies, making it accessible to resource-constrained healthcare facilities across the continent.

MedSol AI has secured strategic partnerships with global pharmaceutical leader AstraZeneca through the Africa Health Innovation Hub, expanding its reach across South Africa, Zambia, Zimbabwe, Nigeria, and Kenya. The company has been recognized internationally, presenting at the UN STI Forum and the G20 Digital Health Summit. Beyond Breast AI, MedSol is developing Wound AI, an AI-powered wound assessment application, further expanding its portfolio of accessible, patient-centered diagnostic tools designed to improve health outcomes and reduce mortality rates across Africa.